S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
S&P 500   4,966.81 (-0.88%)
DOW   37,990.25 (+0.57%)
QQQ   414.07 (-2.21%)
AAPL   165.08 (-1.17%)
MSFT   399.12 (-1.27%)
META   477.67 (-4.81%)
GOOGL   153.59 (-1.55%)
AMZN   173.95 (-2.94%)
TSLA   146.60 (-2.22%)
NVDA   764.87 (-9.67%)
AMD   146.22 (-5.71%)
NIO   3.80 (-5.00%)
BABA   69.02 (+0.20%)
T   16.47 (+0.86%)
F   12.09 (+0.25%)
MU   106.31 (-5.02%)
GE   148.30 (-3.03%)
CGC   8.02 (+2.43%)
DIS   112.11 (-0.28%)
AMC   3.14 (+7.53%)
PFE   25.96 (+2.24%)
PYPL   61.87 (-0.37%)
XOM   119.88 (+1.15%)
Free Trial

Vistagen Therapeutics (VTGN) Earnings Date, Estimates & Call Transcripts

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)
Free VTGN Stock Alerts
$4.75
+0.05 (+1.06%)
(As of 03:40 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Earnings Summary

Upcoming
Earnings Date
Jun. 26Estimated
Actual EPS
(Feb. 13)
-$0.22 Beat By $0.09
Consensus EPS
(Feb. 13)
-$0.31
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

VTGN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

VTGN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Vistagen Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.10)($0.10)($0.10)
Q2 20241($0.08)($0.08)($0.08)
Q3 20241($0.28)($0.28)($0.28)
Q4 20241($0.27)($0.27)($0.27)
FY 20244($0.73)($0.73)($0.73)
Q1 20251($0.38)($0.38)($0.38)
Q2 20251($0.48)($0.48)($0.48)
Q3 20251($0.54)($0.54)($0.54)
Q4 20251($0.65)($0.65)($0.65)
FY 20254($2.05)($2.05)($2.05)

VTGN Earnings Date and Information

Vistagen Therapeutics last announced its quarterly earnings results on February 13th, 2024. The reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.09. The firm earned $0.41 million during the quarter, compared to the consensus estimate of $0.73 million. Vistagen Therapeutics has generated $0.00 earnings per share over the last year. Earnings for Vistagen Therapeutics are expected to decrease in the coming year, from ($1.56) to ($2.00) per share. Vistagen Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, June 26th, 2024 based off prior year's report dates.

Vistagen Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
6/26/2024
Estimated)		------- 
2/13/2024Q3 2024($0.31)($0.22)+$0.09($0.22)$0.73 million$0.41 million
11/9/2023Q2 2024-($0.66)($0.66)($0.66)-$0.28 million
8/10/2023Q1 2024-($0.94)($0.94)($0.94)-$0.18 million
2/7/2023Q3 2023($1.80)($1.50)+$0.30($0.05)$0.31 million$0.18 million
11/10/2022Q2 2023($2.40)($2.40)-($0.08)$0.31 million($0.89) million
8/11/2022Q1 2023($2.70)($3.00)($0.30)($0.10)$0.34 million$0.31 million
6/23/2022Q4 2022($1.80)($2.40)($0.60)($0.08)$0.33 million$0.04 million    
2/10/2022Q3 2022($2.40)($1.50)+$0.90($0.05)$0.33 million$0.36 million    
11/10/2021Q3 2021($1.50)($2.10)($0.60)($0.07)$0.33 million$0.36 million    
8/12/2021Q2 2021($1.50)($1.20)+$0.30($0.04)$0.37 million$0.35 million    
6/28/2021Q1 2021($1.50)($6.00)($4.50)($0.20)$0.31 million$0.44 million    

Vistagen Therapeutics Earnings - Frequently Asked Questions

When is Vistagen Therapeutics's earnings date?

Vistagen Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, June 26th, 2024 based off last year's report dates. Learn more on VTGN's earnings history.

Did Vistagen Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Vistagen Therapeutics (NASDAQ:VTGN) reported ($0.22) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.31) by $0.09. Learn more on analysts' earnings estimate vs. VTGN's actual earnings.

How much revenue does Vistagen Therapeutics generate each year?

Vistagen Therapeutics (NASDAQ:VTGN) has a recorded annual revenue of $1.11 million.

How much profit does Vistagen Therapeutics generate each year?

Vistagen Therapeutics (NASDAQ:VTGN) has a recorded net income of -$59.25 million. VTGN has generated $0.00 earnings per share over the last four quarters.

What is Vistagen Therapeutics's EPS forecast for next year?

Vistagen Therapeutics's earnings are expected to decrease from ($1.56) per share to ($2.00) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:VTGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
My biggest AI fear
Paradigm Press